FOLD Stock Summary and Trading Ideas (Amicus Therapeutics | NASDAQ:FOLD)

Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Amicus Therapeutics trades on the NASDAQ stock market under the symbol FOLD.

As of April 2, 2026, FOLD stock price was flat at $14.44 with 2,884,914 million shares trading.

FOLD has a beta of 0.52, meaning it tends to be less sensitive to market movements. FOLD has a correlation of 0.04 to the broad based SPY ETF.

FOLD has a market cap of $4.53 billion. This is considered a Mid Cap stock.

Last quarter Amicus Therapeutics reported $185 million in Revenue and $.10 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.04.

In the last 3 years, FOLD traded as high as $14.57 and as low as $5.51.

The top ETF exchange traded funds that FOLD belongs to (by Net Assets): VTI, IWM, VB, XBI, VBK.

FOLD has outperformed the market in the last year with a price return of +81.6% while the SPY ETF gained +18.2%. FOLD has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +1.4% and +0.5%, respectively, while the SPY returned -3.6% and -0.6%, respectively.

FOLD support price is $14.42 and resistance is $14.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FOLD shares will trade within this expected range on the day.